#dive

Related news

Immunotherapies, biosimilars to dominate next week of earnings

Published: 24/04/2018

AbbVie, Bristol-Myers, Celgene, Roche, AstraZeneca and others will report first quarter earnings over the coming days. Read more

Source: www.biopharmadive.com
As Spinraza sales fall, Biogen talks up adult SMA opportunity

Published: 24/04/2018

While the big biotech remains optimistic, analysts and investors were skeptical about where growth will come from. Read more

Source: www.biopharmadive.com
Lilly raises sales forecasts as diabetes drugs outperform

Published: 24/04/2018

Strengthening uptake of Trulicity, coupled with higher-than-expected revenue from older insulin products, helped the pharma beat market estimates. Read more

Source: www.biopharmadive.com

Orexigen agrees to sale, but is open to more offers

Published: 24/04/2018

Company leadership realized it's time to slim down and has accepted an acquisition offer. But there's still time for other buyers to submit a bid. Read more

Source: www.biopharmadive.com
Prothena pulls Phase 3 drug, stock plummets

Published: 24/04/2018

The Irish biotech scraped its amyloidosis candidate after a late-stage futility analysis returned disappointing results. Read more

Source: www.biopharmadive.com
Lilly's baricitinib wins FDA panel nod, but still dogged by safety issues

Published: 24/04/2018

Lilly entered the Food and Drug Administration committee meeting on Monday with a fuzzy outlook for its potentially billion-dollar arthritis drug. It left in much the same fashion. Read more

Source: www.biopharmadive.com

Pharma supply chains could use a tech reboot

Published: 23/04/2018

While more prosaic than drug R&D, supply chains are increasingly important as the industry moves toward personalized medicine. Read more

Source: www.biopharmadive.com
Mylan cuts workforce at West Virginia plant by 15%

Published: 23/04/2018

The announcement leaves approximately 3,000 employees at the Morgantown location, a site that is primarily dedicated to production of oral drugs. Read more

Source: www.biopharmadive.com
The Drug Supply Chain Security Act: A progress report

Published: 23/04/2018

Five years in and one enforcement extension later, pharmaceutical companies still have a long way to go to fulfill the goal of true traceability. Read more

Source: www.biopharmadive.com

Top challenges facing drug supply chains

Published: 23/04/2018

Issues like GMP compliance and cold-chain shipping are just two of the hurdles that must be overcome for medicines to travel from drugmakers to patients. Read more

Source: www.biopharmadive.com
As India, China drug industries mature, FDA scrutiny an overhang

Published: 23/04/2018

Rising numbers of warning letters have put production quality in focus, just as both countries turn further toward novel drug R&D. Read more

Source: www.biopharmadive.com
CAR-T ups challenges in pharma supply chain

Published: 23/04/2018

New technology made shipping the cell therapies viable. Now, stakeholders are pushing for more innovation to meet looming commercial demands. Read more

Source: www.biopharmadive.com

Brain Talk: Tackling a crisis while treating the patient

Published: 23/04/2018

The human brain is a marvelous, complex organ. It controls so much of the body, and yet so little is known about it. But every day, new research opens doors to the brain’s inner workings, sheddi ... Read more

Source: www.biopharmadive.com
Pfizer's Herceptin copy hits FDA roadblock

Published: 23/04/2018

Regulators handed Pfizer a Complete Response Letter four months after approving Mylan's copycat version of the breast cancer drug. Read more

Source: www.biopharmadive.com
Novartis bolsters case for siponimod with new data

Published: 23/04/2018

The results support Novartis' filing of the drug, which the pharma hopes will secure FDA approval for secondary progressive MS. Read more

Source: www.biopharmadive.com

Merck antibiotic data positive in Phase 3

Published: 23/04/2018

The promising data moves the pharma closer to a submission to the FDA. Read more

Source: www.biopharmadive.com
Alnylam, Dicerna settle RNAi trade secrets lawsuit

Published: 21/04/2018

Two makers of the gene-silencing technology settled a years-long lawsuit days ahead of a scheduled jury trial date. Read more

Source: www.biopharmadive.com
GW wins panel backing for Epidiolex, looks to FDA decision

Published: 20/04/2018

Following an advisory committee's unanimous recommendation for Epidiolex, GW Pharma awaits a June decision on approval by the regulator. Read more

Source: www.biopharmadive.com

Biogen, facing questions, turns again to Ionis in $1B research deal

Published: 20/04/2018

Tapping the discovery expertise of Ionis, however, may not placate investors eager to see Biogen pad its pipeline with more aggressive dealmaking. Read more

Source: www.biopharmadive.com
Prescribed Reading: Shire on the block; FDA flip-flops

Published: 20/04/2018

There are potentially multiple suitors looking to take out Shire. Elsewhere, the FDA is making surprise reversals. Read more

Source: www.biopharmadive.com
Out-of-pocket drug costs still murky, report underscores

Published: 20/04/2018

A recent look at drug costs for patients from Iqvia suggests they have, on average, fallen. Whether that's partially because of discounts and rebates remains unclear. Read more

Source: www.biopharmadive.com

Related Hashtags

Most read

FACEBOOK

Facebook

Place your ad here
Loading...